Cellectis S.A. | Cash Flow

Fiscal year is January-December. All values EUR Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
26,839.00
1,850.00
20,373.00
60,776.00
91,922.90
74,874.40
Depreciation, Depletion & Amortization
2,255.00
1,345.00
1,745.00
1,998.00
2,988.60
2,014.80
Other Funds
-
908.00
-
-
-
22,814.20
Funds from Operations
21,529.00
5,052.00
4,628.00
5,880.00
30,622.30
50,045.40
Changes in Working Capital
2,676.00
46,778.00
1,392.00
23,679.00
15,769.50
7,710.10
Net Operating Cash Flow
18,853.00
41,726.00
3,236.00
29,559.00
46,391.90
57,755.50
Capital Expenditures
633.00
354.00
3,977.00
12,682.00
2,354.70
Sale of Fixed Assets & Businesses
-
543.00
100.00
21.00
6,351.40
Purchase/Sale of Investments
-
-
-
35,357.00
2,303.30
Net Investing Cash Flow
538.00
1,353.00
6,965.00
48,018.00
1,581.70
Issuance/Reduction of Debt, Net
384.00
1,032.00
564.00
82.00
36.40
Net Financing Cash Flow
5,194.00
57,904.00
198,802.00
438.00
36,585.50
Net Change in Cash
14,249.00
104,788.00
201,891.00
72,736.00
1,606.50
Free Cash Flow
19,423.00
41,379.00
654.00
41,936.00
48,504.60
Net Assets from Acquisitions
-
-
2,850.00
-
-
Other Sources
174.00
-
-
-
-
Change in Capital Stock
5,578.00
59,844.00
199,366.00
520.00
36,621.80
Exchange Rate Effect
52.00
6,511.00
6,818.00
4,403.00
9,831.20
Other Uses
79.00
1,542.00
238.00
-
111.70

About Cellectis

View Profile
Address
8, rue de la Croix Jarry
Paris Ile-de-France 75013
France
Employees -
Website http://www.cellectis.com
Updated 07/08/2019
Cellectis SA is a biopharmaceutical company, which engages in the research and development of genome engineering technology. The company operates through the following business segments: Therapeutics and Plants. The Therapeutics segment is focused on the development of products in the field of immune-oncology and of novel products outside immuno-oncology to treat other human diseases.